0000000000160967

AUTHOR

J.a. Perez Fidalgo

showing 6 related works from this author

18P In vitro analysis of the combination of APR-246 and carboplatin in triple negative breast cancer (TNBC) and high grade serous ovarian cancer (HGS…

2021

P53 pathwaybusiness.industryHematologyCarboplatinIn vitro analysischemistry.chemical_compoundOncologychemistryCell cultureCancer researchSerous ovarian cancerMedicineAurora Kinase AbusinessTriple-negative breast cancerAnnals of Oncology
researchProduct

Incidence of oncogenes in PI3K/AKT and MAPK signaling pathways in breast cancer

2015

Breast cancerOncologybusiness.industrymedicineCancer researchHematologymedicine.diseasebusinessCarcinogenesismedicine.disease_causeProtein kinase BPI3K/AKT/mTOR pathwayMapk signaling pathwayAnnals of Oncology
researchProduct

Management of chemotherapy extravasation: ESMO–EONS Clinical Practice Guidelines

2012

Extravasation is the process by which any liquid (fluid or drug) accidentally leaks into the surrounding tissue. In terms of cancer therapy, extravasation refers to the inadvertent infiltration of chemotherapy into the subcutaneous or subdermal tissues surrounding the intravenous or intra-arterial administration site. Extravasated drugs are classified according to their potential for causing damage as ‘vesicant’, ‘irritant’ and ‘nonvesicant’ (Table 1). Some vesicant drugs are further classified into two groups: DNA binding and non-DNA binding. Allwood et al. (2002) divided the drugs into vesicants, exfoliants, irritants, inflammitants and neutrals.

Drugmedicine.medical_specialtymedicine.medical_treatmentmedia_common.quotation_subjectAntidotesMEDLINECancer therapyAntineoplastic AgentsDiagnosis DifferentialRisk FactorsNeoplasmsHumansMedicineIntensive care medicinemedia_commonChemotherapyOncology (nursing)business.industryGeneral MedicineHematologymedicine.diseaseChemotherapy regimenExtravasationSurgeryClinical PracticeOncologybusinessInfiltration (medical)Extravasation of Diagnostic and Therapeutic MaterialsAnnals of Oncology
researchProduct

No effect of length time bias on the genomic risk in ER+ HER2-stage I-IIA breast cancer (BC) patients according to diagnosis in a screening programme…

2018

Screening programmeOncologymedicine.medical_specialtyBreast cancerOncologybusiness.industryInternal medicineMedicineHematologyExploratory analysisLength time biasbusinessmedicine.diseaseAnnals of Oncology
researchProduct

Association of the rs4567312 variant in the leptin receptor gene with plasma leptin concentrations and lung cancer incidence in the PREDIMED study

2017

medicine.medical_specialtybusiness.industryLeptinIncidence (epidemiology)Hematologymedicine.diseaseLeptin Receptor GenePredimedEndocrinologyOncologyInternal medicineMedicinebusinessLung cancer
researchProduct

Intraperitoneal chemotherapy (IP CT) after cytoreductive surgery benefits survival in epithelial ovarian cancer (EOC): Results of a pooled meta-analy…

2018

Oncologymedicine.medical_specialtybusiness.industryIntraperitoneal chemotherapyHematologylaw.inventionOncologyRandomized controlled triallawInternal medicineMeta-analysisMedicineEpithelial ovarian cancerCytoreductive surgerybusinessAnnals of Oncology
researchProduct